Johnson & Johnson

NYSE : JNJ

$255.56−0.66%

Financials

USD · reported units. Click a value to inspect its source.

Consolidated Statements of Earnings, filing 0000200406-26-000153. USD · reported units.
Reported line item	Mar 30, 2026 to Jun 28, 2026	Mar 31, 2025 to Jun 29, 2025
Income Statement [Abstract]
Sales to customers (Note 9)
Sales to customers percent to salesRatio
Cost of products sold
Cost of products sold percent to salesRatio
Gross profit
Gross Profit Percent To SalesRatio
Selling, marketing and administrative expenses
Selling marketing and administrative expenses percent to salesRatio
Research and development expense
Research and development expense percent to salesRatio
In-process research and development impairments	—	—
In-process research and development percent to salesRatio	—	—
Interest income
Interest income percent to salesRatio
Interest expense, net of portion capitalized
Interest expense, net of portion capitalized percent to salesRatio
Other (income) expense, net
Other (income) expense, net percent to salesRatio
Restructuring (Note 12)
Restructuring charge percent to salesRatio
Earnings before provision for taxes on income
Earnings before provision for taxes on income percent to salesRatio
Provision for taxes on income (Note 5)
Provision for taxes on income percent to salesRatio
Net earnings from continuing operations percent of salesRatio
Net earnings
NET EARNINGS PER SHARE
Total net earnings per share - basic (in dollars per share)USD / share
Total net earnings per share - diluted (in dollars per share)USD / share
Avg. shares outstanding
Basic (shares)Shares
Diluted (shares)Shares

30 line items · 4 reported periodsOriginal filing order · parentheses indicate negative amounts

Each column reflects this filing’s presentation. Original line items and period dates are preserved.